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Abbreviations 
Nonstandard abbreviations used in this thesis were listed in alphabetical order. 
ANOVA Analysis of variance 
AUC  Area under the curve 
CDP  Chlordiazepoxide 
CL  Clearance 
DA  Dopamine 
DSP-1053 6-(2-{4-[4-Bromo-3-(2-methoxyethoxy)benzyl]piperidin-1-yl} 
ethyl)-2,3-dihydro-4H-chromen-4-one benzenesulfonate 
DSR-98776 (3-fluorophenyl)[2-(5-fluoropyridin-2-yl)]-6,7-dihydoro[1,3]oxazolo 
[4,5-c]pyridin-5(4H)-yl]methanone 
EC50  Half maximal effective concentration 
FDSS  Functional drug screening system 
gp  Guinea pig 
Kd  Dissociation constant 
Ki  Inhibition constant 
i.p.  Intraperitoneal 
i.v.  Intravenous 
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I.A.  Intrinsic activity 
IC50  Half maximal inhibitory concentration 
HPLC  High-performance liquid chromatography 
GDP  Guanosine 5’-diphosphate 
GTPγS  Guanosine 5’-(γ-thio) Triphosphate, [35S]- 
hum  Human 
MAP  Methamphetamine 
mGlu receptor Metabotropic glutamate receptor 
MPEP  2-methyl-6-(phenylethynyl)-pyridine 
MPEPy  3-methoxy-5-pyridin-2-ylethynylpyridine 
MTEP  3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine 
OB  Olfactory bulbectomized 
PCPA  4-chloro-DL-phenylalanine methyl ester hydrochloride 
p.o.  Oral, by mouth 
RO50   Dose causing 50% of receptor occupancy 
S.D.  Standard deviation 
S.E.M  Standard error of the mean 
SSRI  Selective serotonin reuptake inhibitor 
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SNRI  Serotonin and norepinephrine reuptake inhibitor 
Vdss  Volume of distribution at steady state 
5-HT  5-hydroxytryptamine (serotonin) 
8-OH-DPAT R-(+)-8-Hydroxy-DPAT 
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General Introduction 
Major depressive disorder is a chronic, debilitating disease that affects approximately 
14.8 million American adults, or about 6.7 percent of the US population aged 18 and 
older (Egede et al., 2007; Kessler et al., 2005; Waraich et al., 2005). The lifetime risk of 
developing major depressive disorder is approximately 15% for men and 30% for 
women (Kessler et al., 2005).  
  Major depressive disorder is associated with various dysfunctions and can have 
serious consequences for both the depressed individuals and families. The disorder 
interferes with the ability to work and pursue usual interests, and makes it extremely 
difficult for patients to maintain social relationships. The first onset of major depressive 
disorder most frequently occurs in young adulthood with recurrent episodes throughout 
life in the vast majority of cases (Keller et al., 1992). Estimates by the World Health 
Organization indicate that major depressive disorder is a leading cause of years lived 
with disability and that the size of the problem appears to be increasing worldwide 
(Murray and Lopez, 1996).  
  An early report by Guze and Robins (1970) indicates that 10-15% of depressed 
patients eventually commit suicide. This rate is supported by recent follow-up studies in 
wider depressed populations (Angst et al., 2002). Patients with mood disorders are 
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believed to have up to 10 years reduced life expectancy, mainly due to the excepted 
increase in suicide risk (Angst et al., 2002). Considering the severity of major 
depressive disorder and its socioeconomic impact, effective pharmacological 
interventions to alleviate patients functional impairments are required. 
  Clinical studies have provided evidence that patients with major depressive disorder 
suffer from impaired monoaminergic neurotransmission, especially serotonin 
neurotransmission. This “monoamine hypothesis” has been supported by several studies 
in both healthy and depressed individuals. Indeed, early studies have shown that agents 
that deplete monoamines, such as reserpine, a vesicular monoamine transporter inhibitor, 
could lead to depression in a small percentage of individuals (Freis, 1954). In addition, 
normal male subjects show significantly elevated scores on the depression scale after 
ingesting a tryptophan-free amino acid mixture which cause marked depletion of plasma 
tryptophan, a chemical precursor of 5-HT, indicating a mood lowering effect of 
decreased brain 5-HT levels in normal males (Young et al., 1985). Moreover, patients 
who experience remission following treatment with antidepressants are vulnerable to 
relapse under depleted monoamines levels (Delgado et al., 1994; Miller et al., 1996). 
These findings led to the hypothesis that reduced levels of monoamine 
neurotransmitters, particularly serotonin, could play an important role in depression. 
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  Strong evidence of abnormal serotonergic neurotransmission in patient with major 
depressive disorder comes from the discovery of prototypical antidepressants. During 
the 1950s, two classes of antidepressants, i.e. tricyclic antidepressants and monoamine 
oxidase inhibitors were discovered serendipitously. In 1957, it was reported that 
although G 22355 (imipramine) was ineffective in schizophrenia despite its closest 
structural resemblance to chlorpromazine, this drug acted as antidepressant in clinical 
use due to its serotonin/norepinephrine reuptake inhibitory activity (Kuhn, 1957, 1958). 
In the same year, two independent groups presented their findings on the antidepressant 
effect of iproniazid, an isonicotinic acid hydrazide for tuberculosis chemotherapy with 
monoamine oxidase inhibitory activity (Crane, 1957; Loomer et al., 1957). These 
findings led to the development of other monoamine oxidase inhibitors and tricyclic 
antidepressants as well as supported the “monoamine hypothesis” suggested by studies 
on induction of depressive state. However, tricyclic antidepressants generally affect 
other off-target receptors, including the muscarinic, histaminic and α1 adrenergic 
receptors, leading to undesired side-effects and reduced tolerability. On the other hand, 
the use of monoamine oxidase inhibitors is limited by the irreversible inhibition of these 
target enzymes and the risk of hypertensive crisis when mixed with certain medications 
or with common tyramine-containing foods. Thus, research has been focusing on the 
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development of selective antidepressants with minimal side effects. Following this trend, 
the first selective serotonin reuptake inhibitor (SSRI), fluvoxamine, was developed by 
Kali-Duphar in 1971 and registered in Switzerland in 1983 (Freeman, 1991). Since the 
introduction of this first SSRI, a number of new SSRIs and serotonin and 
norepinephrine reuptake inhibitors (SNRIs) have been developed and approved 
worldwide. Currently, SSRIs and SNRIs are the first-line treatments for depression due 
to their relatively low potential for side effects. 
  Although SSRIs and SNRIs have dramatically expanded treatment options for major 
depressive disorder, there is still a significant unmet medical need for the management 
of this disorder, including therapeutics delayed onset and treatment resistance 
(Gelenberg et al., 2010; Reeves et al., 2008; Rush et al., 2006; Warden et al., 2007). In 
particular, the results of large-scale clinical trials, including STAR*D, have shown that 
67% of patients do not achieve remission (the score in Quick Inventory of Depressive 
Symptomatology-Self Report is less than or equal to 5) even after standard citalopram 
treatment. Furthermore, about half of remitted patients required over 6-week 
consecutive treatment to achieve remission, indicating SSRI’s delayed therapeutic onset 
(Fava, 2003; Rush et al., 2004; Trivedi et al., 2006). 
  Another shortcoming of the currently available armamentarium for treatment of 
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major depressive disorder is the presence of side effects, including nausea, sexual 
dysfunction, dizziness, sleep disorders, headache and agitation (Gelenberg et al., 2010). 
Studies have actually shown that patients adherence to antidepressants is directly related 
to the frequency and intensity of side effects (Bull et al., 2002; Olfson et al., 2006). 
Clearly, new effective and safe first-line treatments for major depressive disorder are 
necessary to address the needs of patients suffering from this debilitating disorder. 
  In some clinical trials, it has been reported that pindolol, a 5-HT1A/1B and β adrenergic 
receptor partial agonist, may accelerate antidepressants onset and enhance SSRIs 
beneficial effects in treatment-resistant depression (Artigas et al., 1994; Blier and 
Bergeron, 1995; Pérez et al., 1997). This enhancement would be mediated by blockage 
of negative feedback inhibition in response to increased serotonin (5-HT) (Arborelius et 
al., 1996; Bel and Artigas, 1993; Kreiss and Lucki, 1995; Rutter et al., 1994). Further 
evidence to support the role of 5-HT1A receptors in this response comes from the results 
of combination therapy with SSRIs and WAY-100635, a highly selective 5-HT1A 
receptor antagonist (Dawson and Nguyen, 1998; Gartside et al., 1995). 
  On the other hand, activation of 5-HT1A receptor is also considered to shorten SSRIs 
onset by accelerating desensitization of 5-HT1A autoreceptor (Dawson and Watson, 
2009). Therefore, dual-action antidepressants that can modulate 5-HT1A receptor and 
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inhibit 5-HT reuptake could be a plausible option for treatment of major depressive 
disorder with faster onset and higher efficacy than conventional SSRIs (see reviews e.g. 
Celada et al., 2013).  
  There is growing evidence that the glutamatergic system plays an important role in 
the pathophysiology of major depressive disorder (Altamura et al., 1993; Mauri et al., 
1998; Mitani et al., 2006). Especially, it has been reported that ketamine, a dissociative 
anesthetic with N-methyl-D-aspartate blocking effect, produces a rapid long-lasting 
antidepressant effect in a number of clinical studies (Krystal, 2007; Maeng and Zarate, 
2007; Murrough et al., 2013; Pittenger et al., 2007). However, the use of ketamine has 
also been shown to be associated with cognitive impairment and psychotic symptoms 
(Krystal et al., 1994; Lahti et al., 1995; Malhotra et al., 1997), forcing researchers to 
turn their attention to alternative glutamatergic approaches. Recent studies have been 
focusing on the potential role of metabotropic glutamate (mGlu) receptors in depression. 
The mGlu receptors are divided into three groups based on structural homology, signal 
transduction, and pharmacology (Schoepp and conn, 1993). Among them, Group I 
receptors, i.e. mGlu1 and mGlu5, are believed to be involved in the activation of 
phospholipase C, which play an important role in signal transduction pathways (Conn 
and Pin, 1997). Several preclinical studies have shown that inhibitors of the 
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representative mGlu5 receptor, including 2-methyl-6-(phenylethynyl)-pyridine (MPEP) 
and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP), have therapeutic potential 
in the treatment of depression (Kuhn et al., 2002; Pałucha et al., 2005; Pałucha and Pilc, 
2007; Pilc et al., 2002; Swanson et al., 2005; Witkin et al., 2007). In addition, it has 
been suggested that mania, a critical state of bipolar disorder, is caused by malfunction 
in glutamatergic neurotransmission, including abnormal glutamine/glutamate ratio, as 
well as by the putative mechanisms of action of current drugs, including lithium and 
antiepileptics (Krystal et al., 2002; Nonaka et al., 1998; Öngür et al., 2008; Sanacora et 
al., 2003). Although bipolar disorder may be controlled or even prevented by use mood 
stabilizers and atypical antipsychotics, these drugs can produce severe side effects, 
necessitating the development of new therapeutic options. One of the plausible options 
for bipolar disorder with manic state is modulation of glutamatergic neurotransmission.  
  In this study, I evaluated the beneficial effects of two structurally-novel compounds, 
i.e. DSP-1053, a 5-HT reuptake inhibitor with 5-HT1A receptor partial agonistic activity, 
and DSR-98776, a selective mGlu5 receptor negative allosteric modulator in common 
rodent mood disorder models. Because modeling of human neuropsychiatric disorders 
in animals is extremely challenging given the subjective nature of many symptoms, and 
the lack of biomarkers and objective diagnostic test, I used behavioral models with high 
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predictive validity, including the forced swimming test, rat olfactory bulbectomy for 
depressive state and methamphetamine/chlordiazepoxide-induced hyperactivity for 
manic state. Appropriate control substances with proven efficacy in clinical use were 
used as positive controls. As the depression models used in this study were selected to 
reflect the delayed therapeutic onset of current antidepressants in human, all test 
compounds were sub-chronically administered over a period of 1 to 3 weeks.  
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Part-1 
DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, 
displays fast antidepressant effect with minimal undesirable effects in juvenile rats  
 
Abstract 
Enhancement of serotonergic neurotransmission has been the main stream of treatment 
for patients with depression. However, delayed therapeutic onset and undesirable side 
effects are major drawbacks for conventional serotonin reuptake inhibitors. Here, I 
show that DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic 
activity, displays fast antidepressant efficacy with minimal undesirable effects, 
especially nausea and emesis in animal models. DSP-1053 bound human serotonin 
transporter and 5-HT1A receptor with the Ki values of 1.02 ± 0.06 and 5.05 ± 1.07 nM, 
respectively. This compound inhibited the serotonin transporter with an IC50 value of 
2.74 ± 0.41 nM and had an intrinsic activity for 5-HT1A receptors of 70.0 ± 6.3%. In rat 
microdialysis, DSP-1053, given once at 3 and 10 mg kg-1, dose-dependently increased 
extracellular 5-HT levels. In the rat forced swimming test, 2-week administration of 
DSR-1053 (1 mg kg-1) significantly reduced rats immobility time after treatment, 
whereas paroxetine (3 and 10 mg kg-1) required 3-week administration to reduce rats 
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immobility time. In olfactory bulbectomy model, 1 and 2-week administration of 
DSP-1053 reduced both emotional scores and activity in the open field, whereas 
paroxetine required 2 weeks to show similar beneficial effects. Although single 
administration of DSP-1053 induced emesis and vomiting in the rat and Suncus murinus, 
multiple treatment with this compound, but not with paroxetine, decreased the number 
of vomiting episodes. These results highlight the important role of 5-HT1A receptors in 
both the efficacy and tolerability of DSP-1053 as a new therapeutic option for the 
treatment of depression. 
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Purpose 
In Part-1, I report the therapeutic benefits of DSP-1053, a structurally novel 5-HT 
reuptake inhibitor with 5-HT1A receptor partial agonistic activity, in common rodent 
depression models, rat forced swimming test and olfactory bulbectomy model. I also 
compared DSP-1053 potential emetic effect to that of paroxetine in rats and shrews 
(Suncus murinus).  
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Materials and methods 
Animals 
All experimental procedures for the use of animals in this study were reviewed and 
approved by the Institutional Animal Care and Use Committee of Sumitomo Dainippon 
Pharma, Co., Ltd. In part-1, rats were purchased from Charles River Laboratories Japan, 
Inc. (Kanagawa, Japan) or Japan SLC, Inc. (Shizuoka, Japan). Shrews (Suncus murinus) 
were purchased from CLEA Japan, Inc. (Tokyo, Japan). All animals were kept in a room 
with controlled environmental conditions (temperature: 23 ± 3°C, humidity: 55 ± 15%, 
12 h light-dark cycle with light on at 07:00 h) and used after a quarantine period of 7 
days. The animals were given food (CE-2, Oriental Yeast Co., Ltd.) and filtered tap 
water ad libitum. 
 
Materials 
DSP-1053 
(6-(2-{4-[4-Bromo-3-(2-methoxyethoxy)benzyl]piperidin-1-yl}ethyl)-2,3-dihydro-4H-c
hromen-4-one benzenesulfonate) (Figure 1) and paroxetine hydrochloride (paroxetine) 
were synthesized in my laboratories. The rout of synthesis of DSP-1053 has been 
described previously (Nishida et al., 2012). Clomipramine hydrochloride 
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(clomipramine), serotonin hydrochloride (5-HT), dopamine hydrochloride (dopamine), 
imipramine hydrochloride (imipramine), WAY-100635, pindolol, and 
R-(+)-8-Hydroxy-DPAT (8-OH-DPAT) were purchased from Sigma Aldrich Japan 
(Tokyo, Japan). All radioligands were purchased from Perkin Elmer Japan (Kanagawa, 
Japan). For oral (p.o.) administration in rodent models, DSP-1053 and paroxetine were 
dissolved in 0.5% methylcellulose. In the Suncus murinus model, DSP-1053 and 
paroxetine were dissolved in 40% polyethylene glycol. Dosing volume was determined 
based on each animal body weight measured in the morning of each administration day 
(5 mL kg-1). Cell membranes expressing human serotonin transporter and 5-HT1A 
receptor were purchased from Perkin Elmer Japan. Chinese hamster ovary cells 
expressing human serotonin transporter used for [3H]5-HT uptake assay were 
established in my Pharmacology Research Laboratories at Sumitomo Dainippon Pharma 
Co., Ltd.. 
 
Preparation of rat cell membranes 
Five weeks old male rats (Crl:CD(SD)) were sacrificed by decapitation, and their brains 
were rapidly removed and dissected to obtain the cerebral cortex (for serotonin 
transporter binding) and hippocampus (for 5-HT1A binding), which were washed in 
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ice-cold saline and weighed. The tissues were homogenized with a teflon-glass 
homogenizer in reaction buffer (50 mM Tris-HCl buffer containing 120 mM NaCl and 5 
mM KCl (for serotonin transporter) or 50 mM Tris-HCl buffer containing 4 mM CaCl2 
(for 5-HT1A)), and the homogenates were centrifuged at 40,000-48,000×g for 10 min at 
4°C. The obtained pellets were resuspended in the reaction buffer, and the homogenates 
were centrifuged again at 40,000-48,000×g for 10 min at 4°C. The resulting pellets were 
resuspended in 8-10 times their volume of reaction buffer, and the protein 
concentrations were measured by the method of Bradford using the Bio-Rad Protein 
Assay (Bio-Rad Laboratories Co., Ltd.). The cell membranes were diluted with reaction 
buffer to a concentration of 4 mg mL-1. On the day of the experiment, the stored 
membranes were diluted with reaction buffer to a concentration of 447 μg mL-1 (200 
μg/1 assay). 
  
Radioligand binding assay 
In a total volume of 500 μL, 2.5 μL of test substance solution, clomipramine solution (2 
mM), 8-OH-DPAT (2 mM) or dimethyl sulfoxide, 50 μL of [3H]citalopram or 
[3H]8-OH-DPAT solution, and 447.5 μL of cell membranes were mixed. Cell 
membranes expressing human serotonin transporter and 5-HT1A receptor were diluted 
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with the reaction buffer to a final concentration of 1 unit/447.5 μL beforehand. All 
samples were reacted at 25°C for 0.5 (for 5-HT1A) or 1 h (for serotonin transporter) in 
an incubator. The reaction was terminated by addition of 4 mL ice-cold reaction buffer, 
and the cell membranes were collected by vacuum filtration through GF/B glass filters. 
The glass filters were then washed with 4 mL of ice-cold reaction buffer and placed in 
scintillation vials with scintillation fluid. After more than 3 h, the radioactivity in each 
sample was measured with a liquid scintillation counter for 2 min, and the calculated 
dpm value was used for data analysis. In the serotonin transporter binding assay, GF/B 
glass filters were soaked in 0.05% polyethylenimine solution for more than 15 min 
before use. The inhibition constant (Ki) was calculated in Microsoft® Office Excel 2003 
(Microsoft Corporation) using the Cheng-Prusoff equation [Ki = IC50/(1 + ([L]/Kd)], 
where L is the concentration of radioligand in the assay and Kd is the dissociation 
constant of the radioligand for the receptor. s 
 
[3H]5-HT uptake assay 
Phosphate buffered saline containing 0.1 mM CaCl2 and 1 mM MgCl2 was used as 
reaction buffer. One microliter of dimethyl sulfoxide or test substance and 149 μL of 
human serotonin transporter-expressing cells suspension were added to 96 well assay 
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plates. The plates were preincubated at 37°C for 10 min. During that time, dimethyl 
sulfoxide or test substance (DSP-1053, paroxetine, or imipramine) was diluted in 
[3H]5-HT solution in another 96 well plate. After the preincubation, the prepared 
[3H]5-HT solution containing dimethyl sulfoxide or test substance was added to the cell 
suspension, and the mixture was incubated at 37°C for 10 min. Ice cold 3% formamide 
in 0.9% NaCl was added to each well to stop the reaction. All reaction mixtures in the 
96 well plates were then filtered through a glass fiber filter plate prewashed in 200 μL of 
0.3% polyethylenimine and dried under reduced pressure with manifold (Millipore). To 
wash the glass fiber filter, 300 μL of phosphate buffered saline was added and filtrated 
twice. Radioactivity in each sample was measured as described in the previous section. 
 
Guanosine 5’-(γ-thio) Triphosphate, [35S]- (GTPγS) assay for 5-HT1A receptor 
To make up a total volume of 500 μL, 2.5 μL of test substance, 2 mM GTPγS (to 
measure nonspecific binding), dimethyl sulfoxide (to measure basal [35S]GTPγS 
binding), or 20 mM 5-HT (to measure maximal [35S]GTPγS binding), 50 μL of reaction 
buffer (HEPES-NaOH buffer (20 mM, pH 7.4) containing 100 mM NaCl, 10 mM 
MgCl2, 0.1 mM dithiothreitol, and 1 μM guanosine-5’-diphosphate sodium salt (GDP)) 
containing 20 nM [35S]GTPγS, and 447.5 μL of the cell membranes expressing human 
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5-HT1A receptors (1 unit/447.5 μL) were mixed. All samples were allowed to react in an 
incubator set at 25°C for 20 min. The reaction was terminated by adding 4 mL of 
ice-cold reaction buffer, and the cell membranes were collected by vacuum filtration 
using GF/B glass filters. The glass filters were washed twice with 4 mL of ice-cold 
reaction buffer. Radioactivity in each sample was measured as described in the previous 
section. Intrinsic activity was expressed as relative value of the activity of 100 μM 5-HT, 
which was considered to be 100%. 
 
Off-target radioligand binding assays and enzyme assays  
To determine DSP-1053 interaction with off-target receptors and enzymes, 29 receptor 
binding assays and 3 enzyme assays (catechol-O-methyltransferase, monoamine 
oxidase-A and -B) were conducted on my behalf by Sekisui Medical Co., Ltd. The 
receptor binding assays were carried out using standard techniques as summarized in 
Table 3. As for the enzyme assays, pig catechol-O-methyltransferase, human 
monoamine oxidase-A, and -B activity was evaluated using 
S-adenosyl-L-[methyl-14C]-methionine, 5-hydroxy[side chain-2-14C]tryptamine, or 
beta-[ethyl-1-14C]-, PKI as labeled substrate, and the amount of radioactivity was 
quantitated. 
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Pharmacokinetics of DSP-1053 
Pharmacokinetic study of DSP-1053 was carried out in male rats (Crl:CD(SD)) after 
intravenous (i.v.) (1 mg kg-1) and p.o. (10 mg kg-1) administration. At appropriate time 
points after dosing (0.083, 0.25, 0.5, 1, 2, 4, 6, and 24 h for i.v., 0.25, 0.5, 1, 2, 4, 6, and 
24 h for p.o.), blood was sampled from two (for i.v.) or three (for p.o.) different rats. 
Each rat was sampled 8 or 7 times in total. Plasma concentrations of DSP-1053 were 
determined using high-performance liquid chromatography (HPLC)/tandem mass 
spectrometry and analyzed by non-compartmental analysis using WinNonlin (version 
6.3; Pharsight Corporation, CA). 
 
Rat microdialysis 
Surgery 
This experiment was performed using 5-6-week old male rats (Crlj:WI). A vertical 
guide cannula (AG-04; EICOM) was implanted in the right side of the frontal cortex 
(3.7 mm anterior, 3.0 mm lateral, and 1.5 mm ventral from the bregma) of the rat under 
pentobarbital anesthesia [80 mg kg-1, intraperitoneal (i.p.)]. Microdialysis was 
conducted on the day after surgery. A dialysis probe (A-I-4-03; EICOM) was inserted 
into the guide cannula under light anesthesia with isoflurane and continuously perfused 
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by Ringer solution (147 mM NaCl, 4 mM KCl, 2.3 mM CaCl2) at 2 μL min-1 using a 
microsyringe pump. Microdialysate samples (10 μL) were continuously collected for 5 
min at 20-min intervals and automatically injected into the HPLC system. DSP-1053 or 
vehicle was orally administered to the rats at least 3 h after the start of perfusion, that is, 
when stable HPLC baseline values for 5-HT and dopamine were obtained in the 
dialysate samples. Measurement continued for 3 h after drug or vehicle administration.  
Chromatography 
The collected microdialysate samples (10 μL) were separated by HPLC using a PP-ODS 
column (EICOM) and a mobile phase containing 0.1 M phosphate buffer (pH 6.0), 1% 
methanol, 50 mg L-1 ethylenediamine tetraacetic acid disodium, and 500 mg L-1 sodium 
1-decanesulfonate at a flow rate of 0.5 mL min-1. The peaks corresponding to 5-HT and 
dopamine were amperometrically detected using a graphite electrode set at 400 mV with 
an Ag/AgCl reference electrode (RE-100; EICOM). Online data acquisition was 
performed using PowerChrom software (Version 2.2; AD Instruments Pty Ltd.). Before 
performing the microdialysis, the retention time of the HPLC peak for 5-HT and 
dopamine was determined using a standard solution. The peak height (mV) of 5-HT and 
dopamine at each measurement was converted into a percentage of the average of the 
last 4 pre-drug baseline values (percentage of baseline). 
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Rat forced swimming test 
Test-compounds antidepressant-like activity was assessed as previously described 
(Porsolt et al., 1978) with slight modifications. In the training session (Day 1), each 
animal (5-6-week old male rats (Crlj:WI)) was gently placed into a plastic cylinder (40 
cm in height, 19 cm in diameter) containing 5.8 L of water set at 25 ± 1°C. Fifteen 
minutes after the beginning of the training session, the animal was removed from the 
water and returned to its home cage. Test compounds dosing suspensions were 
administered to animals in a blind manner 15 min after the end of the training session. 
From Day 2 to Day 13 or Day 20, the animals were administered the dosing suspensions 
once a day between 7:00AM and 7:00PM. In the test session (Day 14 or Day 21), the 
animals were treated with the dosing suspensions as described in the training session, 
and the swimming test was performed for 5 min in the same manner as in the training 
session. In the swimming test, the behavior of each animal was horizontally recorded 
onto a DVD recorder using a video camera. An animal was judged to be immobile 
whenever it remained floating on the water without moving its body or forepaws, except 
for slight movements to maintain posture. The total time the animal remained immobile 
was defined as immobility time. An observer blinded to test compounds doses measured 
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the immobility time. 
 
Olfactory bulbectomy 
Surgery 
The test was performed using 6-7-week old male rats (Crlj:WI). Bilateral olfactory 
bulbectomy was performed on rats anesthetized with pentobarbital (50 mg kg-1; i.p.), 
essentially as previously described (Cryan et al., 1999). The head was shaved and a 
midline sagittal incision was made extending at 1 cm rostral to bregma. A burr hole was 
drilled at points 7 mm anterior to bregma and 2 mm either side of the midline at a point 
corresponding to the posterior margin of the orbit of the eye. The olfactory bulbs were 
removed by suction, and the burr holes filled with a hemostatic sponge (Spongel; 
Astellas Pharma Inc.). Tetracycline powder was applied to the wound prior to closure. 
Sham-operated rats underwent the same procedure with the dura above the bulbs 
punctured, but the bulbs left intact. Following surgery, the animals were allowed 7 days 
recovery prior to drug administration. During recovery, the general condition of each 
animal was monitored.  
Emotional scoring 
Emotional scoring was conducted, essentially as previously reported (Cairncross et al., 
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1978; Gomita et al., 1983). Emotional scoring consisted of the following five tests; 1) 
response to a stick presented just in front of the nose, 2) response to a puff of air blown 
sharply onto the rat’s back, 3) response to grasping the animal, 4) response to tail 
pinching by a forceps, 5) vocalization during scoring. In each of the tests numbered 1) 
to 4), responses were graded as follows: 0 (no response), 1 (slight response), 2 
(moderate response), 3 (marked response), or 4 (extreme response). In test 5), 
vocalization was graded as follows: 0 (no vocalization), 1 (occasional vocalization), or 2 
(extensive vocalization). Emotional scoring was performed in animals’ home cages. The 
scores in each scoring system were added to give a single emotional score for each 
individual animal. The maximum emotional score was 18. Animals emotional scoring 
was performed just before the first drug administration (pre), and on the day after the 
open field test (post). 
Open field test 
The open field test was carried out, essentially as described elsewhere (Cryan et al., 
1999). Each rat was placed onto the center of the open-field apparatus, and the number 
of line crosses over a 5-min period was recorded.  
 
Conditioned taste aversion test in rats 
The test was performed using 10-week old male rats (Slc:SD). Drinking water was 
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removed overnight (from 18:00 until 09:00 h) prior to the start of the experiment. On 
the following 2 days, water was first given for 60 min, and then ad libitum from 12:00 
until 18:00 h. On day 3, all rats had access to a 0.5 % saccharin solution for 60 min 
instead of water. At 10:20 h of day 3, the animals were dosed with DSP-1053 or vehicle. 
Water was then made available ad libitum for the rest of the day and removed overnight 
(from 18:00 until 09:00 h). On the test day (day 4), the animals had again access to 
0.5% saccharin solution for 60 min in the absence of test compound. Rats saccharin 
consumption was measured for each 60-min period on day 3 and 4, and saccharin intake 
ratio was calculated as follows. 
(Saccharin intake ratio) = (saccharin intake on day 4) / (saccharin intake on day 3) 
 
Evaluation of emesis in Suncus murinus 
Male Jic:SUN-Her, 5 weeks (body weight: 40 - 63 g) (experiment 1), or 10 weeks (body 
weight: 53 - 73 g) (experiment 2) of age at the initiation of dosing were used in this 
study. 
Experiment 1 
DSP-1053 (10, 30, 60, or 100 mg kg-1) or 40% polyethylene glycol was orally 
administered to the animals, and the number of animals that vomited as well as the 
number of vomiting episodes were counted for 60 min. Paroxetine-induced emesis, as 
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evaluated under the same protocol (Mine et al., 2013), was used as reference.  
Experiment 2 
On the first day of the experiment, DSP-1053 (60 mg kg-1), paroxetine (60 mg kg-1), or 
40% polyethylene glycol was orally administered to the animals and the number of 
vomiting episodes was counted. Animals that showed emesis on the first day in each 
group (9 of 19 in DSP-1053 group, 12 of 19 in paroxetine group), and 3 animals in 40% 
polyethylene glycol group were subsequently dosed once a day for 7 days with 
DSP-1053 (60 mg kg-1), paroxetine (60 mg kg-1), or 40% polyethylene glycol, 
respectively, and the number of animals that vomited as well as the number of vomiting 
episodes was counted for 60 min after administration on each day. 
 
Data analysis 
Scatchard plots approximated by regression line with Microsoft® Office Excel 2003 
(Microsoft Corporation) were used to calculate Kd value in each binding assay. The IC50 
value in each binding assay and the maximal specific binding of each test substance 
(intrinsic activity (I.A.) of the test substance) as well as EC50 values in GTPγS assay 
were determined by fitting logistic curve using “Dx calculation (logistic curve fitting) 
with measured value input function” method in Stat Prelinica Version 1.0.3.  
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  In rat microdialysis, data are presented as time course changes in peak height and in 
cumulative values of percentage of baseline over 3 h after drug administration (AUC 
(0-180 min)). Cumulative data were analyzed with one-way analysis of variance 
(ANOVA) followed post-hoc parametric Dunnett’s multiple comparison test. 
Differences in immobility time in the rat forced swimming test between test compounds 
treated groups and the vehicle treated group were analyzed with one-way ANOVA 
followed post-hoc parametric Dunnett’s multiple comparison test.  
  In olfactory bulbectomy, the statistical significance of differences in emotional scores 
and the number of line crosses between each group was assessed with three-way 
ANOVA, and post-hoc individual group comparison were made with t-test and 
parametric Dunnett’s multiple comparison test. 
  In rat conditioned taste aversion model, differences in water or saccharin and 
saccharin intake ratio between DSP-1053 treated group and the vehicle treated group 
were analyzed with one-way ANOVA followed post-hoc parametric Tukey’s multiple 
comparison test. 
  In emesis test using Suncus murinus, data analysis was conducted as previously 
reported (Mine et al., 2013). In experiment 1, differences in incidence of vomiting 
between the vehicle treated group and compounds treated groups were analyzed by 
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Fisher’s exact test. The number of emetic episodes was determined as average for all 
animals that vomited. In experiment 2, the number of emetic episodes was determined 
as average for all tested animals. Differences in the number of emetic episodes between 
Day 1 and Day 2 to Day 7 of treatment were analyzed with one-way ANOVA followed 
post-hoc parametric Dunnett’s multiple comparison test. 
  In all animal experiments, Stat Prelinica Version 1.2 was used as analysis software. 
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Results 
DSP-1053 in vitro binding to the serotonin transporter 
DSP-1053 inhibited the binding of [3H]citalopram to human and rat serotonin 
transporter, with Ki values of 1.02 ± 0.06 and 0.489 ± 0.039 nM [mean ± S.E.M. 
duplicate, 3 independent experiments (n=3)], respectively. In addition, in 5-HT uptake 
assay using Chinese hamster ovary cells expressing human serotonin transporter, 
DSP-1053 inhibited [3H]5-HT uptake with an IC50 value of 2.47 ± 0.41 (n=3). In both 
assays, DSP-1053 binding affinity for human serotonin transporter was lower than that 
of paroxetime, but higher than that of imipramine (Table 1). 
 
DSP-1053 in vitro binding to the 5-HT1A receptor 
DSP-1053 inhibited the binding of [3H]8-OH-DPAT to human and rat 5-HT1A receptor 
with Ki values of 5.05 ± 1.07 and 5.09 ± 1.03 nM (mean ± S.E.M. n=3), respectively. In 
GTPγS assay using Chinese hamster ovary cell membrane expressing human 5-HT1A 
receptor, DSP-1053 displayed I.A. of 70.0 ± 6.3% (relative value of the activity of 100 
μM 5-HT) [EC50; 98.0 ± 34.9 nM] (n=3). DSP-1053 binding affinity for human 5-HT1A 
receptor was comparable to that of pindolol or 8-OH-DPAT, but lower than that of 
WAY-100635. On the other hand, DSP-1053 I.A. for 5-HT1A receptor was higher than 
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that of WAY-100635 or pindolol, but lower than that of 8-OH-DPAT (Table 2). 
 
DSP-1053 binding to off-target receptors and enzymes 
As shown in Table 3, DSP-1053 (1 μM) showed affinity for histamine H1 receptor with 
Ki value of 7.46 ± 1.37 nM (mean ± S.E.M. n=3). DSP binding affinity for the other 28 
tested receptors was weak (Ki values > 100 nM). Moreover, DSP-1053 (1 μM) did not 
inhibit pig catechol-O-methyltransferase, human monoamine oxidase-A, and -B 
(percent inhibition; 0.00, 5.28 and 0.19 %, respectively). 
 
Pharmacokinetics of DSP-1053 
DSP-1053 reached maximum plasma levels within 1 h after p.o. administration with 
7.3% bioavailability (Figure 2). DSP-1053 clearance (CL) and volume of distribution at 
steady state (Vdss) after injection were 57.6 mL min-1 kg-1 and 5.1 L kg-1, respectively. 
In all DSP-1053 in vivo studies, dosing time was selected based on the above 
pharmacokinetic parameters. 
 
Effects of DSP-1053 on extracellular 5-HT and dopamine levels in the frontal 
cortex of rats 
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Basal microdialysate levels of 5-HT and dopamine in the rat frontal cortex were 0.355 ± 
0.025 and 0.305 ± 0.019 pg/10 μl (n=17), respectively. DSP-1053 increased 5-HT 
extracellular levels in the rat frontal cortex. This increase reached a maximum of 180 ± 
25.9% and 264 ± 58.0% (mean ± S.E.M.) of baseline value 100 min after DSP-1053 
administration at 3 and 10 mg kg-1, respectively (Figure 3A). In addition, DSP-1053 (3 
and 10 mg kg-1) significantly increased cortical 5-HT cumulative value over 3 h after 
administration [F(3,13) = 30.90, p < 0.05] (Figure 3B). On the other hand, DSP-1053 
didn’t affect dopamine extracellular levels in the rat frontal cortex at any dose [F(3,13) 
= 0.13, p > 0.05] (Figure 3C, D). 
 
DSP-1053 antidepressant-like effect in the rat forced swimming test  
As shown in Figure 4A, DSP-1053 significantly decreased immobility time following a 
2-week consecutive administration at 1 mg kg-1 compared to the vehicle [F(3,60) = 5.01, 
p < 0.05]. On the other hand, animals treated with paroxetine (3 and 10 mg kg-1) for 
3-week had reduced immobility time compared to the animals treated with the vehicle 
[F(2,51) = 4.64, p < 0.05] (Figure 4B). Treatment with paroxetine for 2-week had no 
effect on rats immobility time [F(3,60) = 1.59, p > 0.05] (Figure 4C). 
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DSP-1053 antidepressant-like effect in the rat olfactory bulbectomy test 
Effects on emotional scores 
Figure 5A and B show the effects of 1-week and 2-week administration of DSP-1053 on 
emotional scores of sham-operated and olfactory bulbectomized animals. Three-way 
(drug, surgery and dosing period) ANOVA revealed no main effect for drug × surgery × 
dosing period, drug × dosing period and surgery × dosing period interaction and a 
significant main effect for drug × surgery interaction [drug × surgery × dosing period 
interaction, F(15,144) = 1.16, p > 0.05; drug × dosing period interaction, F(15,144) = 
0.17, p > 0.05; surgery × dosing period interaction, F(15,144) = 1.84, p > 0.05; drug × 
surgery interaction, F(15,144) = 22.55, p < 0.05]. Olfactory bulbectomy significantly 
increased emotional scores [F(15,144) = 598.83, p < 0.05]. Post-hoc test analysis 
showed that in olfactory bulbectomized animals, DSP-1053 (0.3, 1 and 3 mg/kg) 
produced a significant decrease in emotional scores [F(3,76) = 30.58, p < 0.05] and no 
effect in the sham-operated animals [F(3,76) = 0.21, p > 0.05]. Figure 5C and D show 
the effects of 1-week and 2-week administration of paroxetine on emotional scores of 
sham-operated and olfactory bulbectomized animals. Three-way ANOVA revealed a 
significant main effect for drug × surgery × dosing period interaction [F(13,125) = 5.18, 
p < 0.05]. In 1-week administration group, sub-effect two-way (drug and surgery) 
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ANOVA revealed that paroxetine didn’t alter emotional scores compared to the vehicle 
[F(5,54) = 0.95, p > 0.05]. On the other hand, olfactory bulbectomy significantly 
increased emotional scores [F(5,54) = 453.49, p < 0.05], and it didn’t significantly 
affect the drug effect [drug × surgery interaction, F(5,54) = 1.94, p > 0.05]. In 2-week 
administration group, sub-effect two-way (drug and surgery) ANOVA revealed a 
significant main effect for drug × surgery interaction [F(7,71) = 4.16, p < 0.05]. 
Post-hoc test analysis showed that in olfactory bulbectomized animals, paroxetine (3 
and 10 mg/kg) produced a significant decrease in emotional scores [F(3,35) = 7.38, p < 
0.05] and no effect in the sham-operated animals [F(3,36) = 1.26, p > 0.05]. 
 
Effects on the number of line crosses 
Figure 6A and B show the effects of 1-week and 2-week administration of DSP-1053 on 
the number of line crosses of sham-operated and olfactory bulbectomized animals. 
Three-way ANOVA revealed no main effect for drug × surgery × dosing period, drug × 
dosing period and surgery × dosing period interaction and a significant main effect for 
drug × surgery interaction [drug × surgery × dosing period interaction, F(15,144) = 0.87, 
p > 0.05; drug × dosing period interaction, F(15,144) = 0.80, p > 0.05; surgery × dosing 
period interaction, F(15,144) = 0.58, p > 0.05; drug × surgery interaction, F(15,144) = 
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7.25, p < 0.05]. Olfactory bulbectomy significantly increased the number of line crosses 
[F(15,144) = 41.65, p < 0.05]. Post-hoc test analysis showed that in olfactory 
bulbectomized animals, DSP-1053 (0.3, 1 and 3 mg/kg) produced a significant decrease 
in the number of line crosses [F(3,76) = 7.85, p < 0.05] and no effect in the 
sham-operated animals [F(3,76) = 1.55, p > 0.05]. Figure 6C and D show the effects of 
1-week and 2-week administration of paroxetine on the number of line crosses of 
sham-operated and olfactory bulbectomized animals. Three-way ANOVA revealed a 
significant main effect for drug × surgery × dosing period interaction [F(13,125) = 4.27, 
p < 0.05]. In 1-week administration group, sub-effect two-way (drug and surgery) 
ANOVA revealed that paroxetine didn’t alter the number of line crosses compared to the 
vehicle [F(5,54) = 0.78, p > 0.05]. On the other hand, olfactory bulbectomy 
significantly increased the number of line crosses [F(5,54) = 43.03, p < 0.05], and it 
didn’t significantly affect the drug effect [drug × surgery interaction, F(5,54) = 0.76, p > 
0.05]. In 2-week administration group, sub-effect two-way (drug and surgery) ANOVA 
revealed a significant main effect for drug × surgery interaction [F(7,71) = 2.97, p < 
0.05]. Post-hoc test analysis showed that in olfactory bulbectomized animals, paroxetine 
(10 mg/kg) produced a significant decrease in the number of line crosses [F(3,35) = 
2.92, p < 0.05] and no effect in the sham-operated animals [F(3,36) = 2.58, p > 0.05]. 
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DSP-1053 potential to induce emesis in rats conditioned taste aversion test 
On Day 4, DSP-1053 (100 mg kg-1) significantly inhibited saccharin consumption 24 h 
after administration compared to the vehicle [F(2,15) = 4.73, p < 0.05] (Figure 7A). 
Saccharine intake ratio was significantly inhibited at the doses of 60 and 100 mg kg-1  
[F(2,15) = 22.77, p < 0.05] (Figure 7B). 
 
DSP-1053 potential to induce emesis in Suncus murinus 
In experiment 1, DSP-1053 at the dose of 10, 30, or 60 mg kg-1 induced emesis in 0, 1, 
or 3 out of 6 animals, respectively, while, as shown in Table 4, paroxetine at 10, 30, or 
60 mg kg-1 induced emesis in 0, 2, or 6 out of 6 animals, respectively (Mine et al., 2013). 
In experiment 2, both DSP-1053 (60 mg kg-1) and paroxetine (60 mg kg-1) induced 
emesis in 9 and 12 out of 19 animals, respectively. Figure 8 shows the incidence of 
vomiting and the number of vomiting episodes during a 60 min period in each day of a 
7-day consecutive administration of DSP-1053 or paroxetine. A significant reduction in 
the number of vomiting episodes was observed from Day 2 in DSP-1053 treated group 
[F(6,56) = 5.60, p < 0.05]. On the other hand, repeated administration of paroxetine 
didn’t have significant effect on the number of vomiting episodes throughout the 7-day 
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administration period [F(6,77) = 1.64, p > 0.05].  
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Discussion 
In this study, I evaluated the in vitro and in vivo profile of DSP-1053, a structurally 
novel 5-HT reuptake inhibitor with 5-HT1A partial agonistic activity. My results show 
that DSP-1053 exhibits a potent fast antidepressant-like effect with minimal undesirable 
effects in animal models.  
  My in vitro experiments demonstrate that DSP-1053 works as a serotonin reuptake 
inhibitor with relatively high partial agonistic activity for 5-HT1A receptor (70.0 ± 6.3%). 
It is well reported that SSRIs enhancement of 5-HT neurotransmission is dampened by 
activation of somatodendritic or postsynaptic 5-HT1A receptors (Artigas et al., 1996, 
Casanovas et al., 1999). However, acute increase in 5-HT levels in the rat frontal cortex 
has also been achieved when antidepressants are used in combination with pindolol, a 
weak 5-HT1A receptor partial agonist or WAY-100635, a 5-HT1A receptor antagonist 
(Hughes et al., 2007; Jerning et al., 2002; Papp et al., 2006; Pauwels et al., 1997; 
Watson et al., 2000). On the other hand, acute treatment with DSP-1053, which has a 
relatively high 5-HT1A partial agonistic activity, enhanced 5-HT neurotransmission in 
the rat prefrontal cortex without affecting dopamine neurotransmission. It has been 
suggested that stimulation of 5-HT1A receptors enhances dopamine neurotransmission 
via activation of presynaptic 5-HT1A receptors expressed in the ventral tegmental area 
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(Lejeune et al., 1997; Millan et al., 1997). This indicates that DSP-1053 may act as 
antagonist for presynaptic 5-HT1A receptors. On the other hand, the prolonged 
stimulation of 5-HT neurotransmission that occurs during chronic SSRI treatment has 
been reported to desensitize raphe 5-HT1A autoreceptors, as assessed by single unit 
recordings and brain microdialysis (Arborelius et al., 1995; Blier and de Montigny, 
1994; Invernizzi et al., 1994; Le Poul et al., 1995). These findings suggest that 
DSP-1053 acute enhancement of 5-HT release may be attributed to early desensitization 
of 5-HT1A receptors. Like DSP-1053, vilazodone and vortioxetine, which inhibit the 
serotonin transporter with 5-HT1A partial or full agonistic activity, have been reported to 
enhance 5-HT neurotransmission by acute treatment (Hughes et al., 2005; Pehrson et al., 
2013). Although further studies are needed to clarify the exact contribution of 5-HT1A 
partial activation in DSP-1053 beneficial effects, evidence highlighting the involvement 
of this receptor in antidepressants early onset suggests that both inhibition and 
activation of 5-HT1A receptors would fasten SSRI efficacy.  
  In the rat forced swimming test, which is the most commonly used behavioral test to 
assess potential antidepressants efficacy (see reviews e.g. Cryan and Mombereau, 2004; 
Pollak et al., 2008), DSP-1053 decreased rats immobility time after 2 weeks treatment, 
while treatment with paroxetine, a representative SSRI, required 3 weeks for 
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comparable efficacy. These results indicate that DSP-1053 would have earlier onset of 
efficacy than SSRIs. Next, I evaluated the efficacy and onset of DSP-1053 in the rat 
olfactory bulbectomy model. The rat olfactory bulbectomy model is a suitable tool for 
investigating antidepressants onset, because olfactory bulbectomy-induced behavioral 
abnormalities can be reversed by chronic, but not acute, antidepressants treatment 
(Kelly et al., 1997; Roche et al., 2007, 2008). As shown in Figures 5, 6, DSP-1053 
exerted significant antidepressant-like effects after 1-week administration, while 
paroxetine required 2-week treatment to show similar efficacy. This indicates that 
DSP-1053 has early onset of action compared to paroxetine. On the other hand, 
DSP-1053 improvement of hyperemotional behavior may reflect an anxiolytic-like 
effect as rats muricidal behavior has been reported to be improved by anxiolytics 
(Takaoka et al., 1988). In the rat forced swimming test and olfactory bulbectomy model, 
DSP-1053 showed efficacy at a lower dose range than the doses that increased 5-HT 
level in the rat frontal cortex. The following two reasons might explain this discrepancy. 
One major difference between the olfactory bulbectomy test and rat microdialysis is the 
duration of drug administration. That is, chronic treatment with DSP-1053 is considered 
to induce further desensitization of 5-HT1A receptors and enhancement of 5-HT 
neurotransmission compared to single administration. As for the second reason, it is 
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believed that activation of postsynaptic 5-HT1A receptors contributes to DSP-1053 low 
dose antidepressant-like effect. This hypothesis may be supported by evidence showing 
that postsynaptic 5-HT1A receptors are particularly important in antidepressant response 
(Blier and Ward, 2003). However, further investigation of changes in neurotransmission 
after chronic administration of DSP-1053 as well as evaluation of DSP-1053 effects at 
the efficacy pre- and post-synaptic regions would be necessary to confirm the above 
hypothesis.  
  Next, I investigated DSP-1053 potential for inducing emesis in experimental animals, 
because emesis is one of the common side effects of SSRIs (Brambilla et al., 2005; 
Gelenberg et al., 2010). As emesis is uncommon in rodents, I used the conditioned taste 
aversion test, which is recognized as a highly reliable tool for evaluation of behavioral 
alterations induced by radiation or other environmental agents that cause emesis and 
nausea (Rabin and Hunt, 1986). DSP-1053 significantly inhibited saccharin 
consumption compared to vehicle treatment, indicating this compound potential for 
nausea or feeling of vomiting. On Day 3, the lower saccharine consumption was 
observed in vehicle treated rats than Day 2. This phenomenon was also reported in 
previous study (Hatcher et al., 1998). Although the reason of this lower saccharine 
intake is not clear, the first experiment for new taste might defeat the appetite for water.  
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In addition, I used shrews (Suncus murinus) which can positively respond to various 
emetic stimuli including motion, X-radiation and emetogenic substances such as 
cisplatin and SSRI (Matsuki et al., 1992; Mine et al., 2013; Okada et al., 1995) to 
further evaluate DSP-1053 potential for emesis. As a result, single administration of 
DSP-1053 induced emesis in a dose-dependent manner, suggesting that acute treatment 
with DSP-1053 can produce emesis. This undesirable effect may be due to acute 
increase in 5-HT level following inhibition of serotonin transporter. On the other hand, 
the number of vomiting episodes decreased following multiple dosing with DSP-1053, 
but not paroxetine. This finding indicates that repeated treatment with DSP-1053 results 
in a fast adaptation to the feeling of nausea and therefore reduction in emetic episodes. 
It has been reported that enhancement of 5-HT1A receptors activation can reduce 
vomiting and nausea in animals (Rock et al., 2014; Wolff and Leander, 1997). This 
beneficial effect is believed to be trigged by attenuation of 5-HT neurotransmission 
following somatodendritic 5-HT1A receptors activation. On the other hand, DSP-1053 
enhanced 5-HT neurotransmission in rat microdialysis, indicating fast desensitization of 
the serotonergic system play an important role in the fast adaptation to the feeling of 
nausea and therefore emesis. It is reported that SSRI-induced nausea typically ceases as 
treatment continues (Peretti et al., 2000). Although the precise mechanism of 
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SSRI-induced nausea is still unclear, 5-HT3 receptors in the chemoreceptor trigger zone 
are considered to have an important role, as 5-HT3 antagonists, including cisapride and 
ondansetron, are reported to reduce SSRI-induced gastrointestinal side effects (Bergeron 
and Blier, 1994). In addition, HTR3B gene polymorphisms are considered as significant 
predictors of paroxetine-induced nausea (Sugai et al., 2006). Moreover, chronic 
activation of ionotropic 5-HT3 receptors is believed to produce significant 
desensitization of 5-HT3 receptors (see review e.g. Jackson and Yakel, 1995). Taken 
together, these findings indicate that DSP-1053 fast onset enhancement of 5-HT 
neurotransmission induces fast desensitization of 5-HT3 receptors, resulting in fast 
adaptation to the feeling of nausea and emesis. However, further work is needed to 
confirm this hypothesis. 
  In conclusion, this study shows that DSP-1053, a novel serotonin reuptake inhibitor 
with 5-HT1A receptor partial agonistic activity, shows fast antidepressant-like effect and 
fast adaptation to the feeling of nausea and emesis in rodent and shrew models. These 
results highlight the important role of 5-HT1A receptors in both the efficacy and 
tolerability of DSP-1053 as a new therapeutic option for the treatment of depression. 
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Figures and Tables 
 
 
Figure 1 
Chemical structure of DSP-1053 
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Figure 2 
DSP-1053 plasma concentrations after single p.o. and i.v. administration to fed 
male rats. Data are the mean ± S.D. (n=2 (for i.v.) or n=3 (for p.o.)).  
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Figure 3 
Effects of DSP-1053 on 5-HT and dopamine levels in rat frontal cortex. (A, C) 
Time-course changes in 5-HT and dopamine (DA) levels in the rat frontal 
cortex after DSP-1053 p.o. administration. Each point with a vertical bar 
represents the mean ± S.E.M of percentage baseline value. (B, D) Effects of 
DSP-1053 on extracellular 5-HT and DA levels in the rat frontal cortex. Each 
column with vertical bar represents the mean ± S.E.M of AUC of 5-HT or DA 
percent over 3 h. ** p < 0.01, compared to the vehicle-treated group using 
parametric Dunnett’s multiple comparison test. Vehicle group, n=6; DSP-1053 
1 and 3 mg kg-1 groups, n=4; and DSP-1053 10 mg kg-1, n=3. 
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Figure 4 
Effects of DSP-1053 (A) and paroxetine (B and C) on immobility time in the 
forced swimming test in rat. Each bar represents the mean ± S.E.M of 
immobility time during a 5 min test session (n=16-18 per group). *p < 0.05, ** 
p < 0.01, compared to the vehicle-treated group using parametric Dunnett’s 
multiple comparison test.  
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Figure 5 
Effects of DSP-1053 (A, B) and paroxetine (C, D) on emotional score in 
sham-operated and olfactory bulbectomized (OB) rats. Each bar represents the 
mean ± S.E.M (n=9-10 per group). ## p < 0.01 OB group vs sham-operated 
group (t-test with two-sided significance of 5%). * p < 0.05 , ** p < 0.01 vs 
vehicle treated subgroup in OB group (parametric Dunnett’s multiple 
comparison test with two-sided significance of 5%). 
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Figure 6 
Effects of DSP-1053 (A, B) and paroxetine (C, D) on the number of line 
crosses in sham-operated and OB rats. Each bar represents the mean ± S.E.M 
(n=9-10 per group). ## p < 0.01 OB group vs sham-operated group with vehicle 
treatment (t-test with two-sided significance of 5%). * p < 0.05 , ** p < 0.01 vs 
vehicle treated subgroup in OB group (parametric Dunnett’s multiple 
comparison test with two-sided significance of 5%). 
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Figure 7 
Effect of DSP-1053 on saccharin consumption in rat conditioned taste aversion 
test. (A) Each bar represents the mean ±  S.E.M of water or saccharin 
consumption (g) on each day (n=6). (B) Each bar represents the mean ± 
S.E.M of saccharin consumption ratio of day 4/day 3. * p < 0.05, ** p < 0.01, 
compared with the vehicle-treated group using Turkey’s test.  
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Figure 8 
Effects of 7-day treatment with DSP-1053 or paroxetine on the number of 
vomiting episodes in Suncus murinus. Each column represents the mean ± 
S.E.M. of the number of emetic episodes. The number above each column 
represents the incidence of vomiting as the number of animals that vomited / 
the number of animals tested. * p < 0.05, ** p < 0.01, significantly different 
from the number of vomiting episodes observed in Day 1 using Dunnett’s 
multiple comparison test. 
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Table 1  
DSP-1053 in vitro binding to the serotonin transporter 
 
  Drug IC50 (nM) Kd (nM) Ki (nM) 
Human SERT binding     
 DSP-1053 1.56 ± 0.09 
3.45 ± 0.19 
1.02 ± 0.06 
 Paroxetine 0.279 ± 0.014 0.183 ± 0.008 
 Imipramine 3.60 ± 0.07 2.36 ± 0.04 
Rat SERT binding   
 DSP-1053 8.84 ± 0.07 1.14 ± 0.02 0.489 ± 0.039 
5-HT uptake inhibition   
 DSP-1053 2.47 ± 0.41 
- -  Paroxetine 0.181 ± 0.020 
  Imipramine 3.73 ± 0.27 
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Table 2 
DSP-1053 in vitro binding to the 5-HT1A receptor 
 
  Drug 
IC50 / EC50 
(nM) 
Kd (nM) Ki (nM) I.A. (%) 
Human 5-HT1A binding      
 DSP-1053 9.92 ± 2.11 
0.313 ± 0.045 
5.05 ± 1.07 
- 
 WAY-100635 0.958 ± 0.130 0.420 ± 0.060 
 Pindolol 21.6 ± 3.0 9.39 ± 1.30 
 8-OH-DPAT 10.3 ± 1.5 4.47 ± 0.64 
Rat 5-HT1A binding    
 DSP-1053 10.7 ± 2.1 0.275 ± 0.009 5.09 ± 1.03 - 
GTPγS binding    
 DSP-1053 98.0 ± 34.9 
- - 
70.0 ± 6.3 
 WAY-100635 n.d. 2.60 ± 3.88 
 Pindolol n.d. 13.3 ± 3.8 
  8-OH-DPAT 58.0 ± 11.3 102 ± 1 
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Table 3 
DSP-1053 (1 μM) inhibition of radioligand binding to various receptors 
 
Target Radioligand 
Conc. 
(nM) 
% inhibition 
at 1 μM 
Ki (nM) 
(n=3) 
hum adrenergic α1A [125I] HEAT 0.15 57 528 ± 45 
hum adrenergic α1B [3H] Prazosin 1.2 1 - 
hum adrenergic α2A [3H] Rawolscine 1.3 26 - 
hum adrenergic α2B [3H] Rawolscine 1.3 6 - 
hum adrenergic α2C [3H] Rawolscine 1.3 41 - 
hum adrenergic β1 [3H] (-)-CGP-12177 0.21 14 - 
hum adrenergic β2 [3H] (-)-CGP-12177 0.21 22 - 
hum adrenergic β3 [125I] (-)-Cyanopindolol 0.060 19 - 
hum dopamine D1 [3H] SCH-23390 0.48 4 - 
hum dopamine D2L [3H] Spiperone 2.0 35 - 
hum dopamine D3 [3H] R-(+)7-OH-DPAT 0.38 65 249 ± 21 
rat GABAA [3H] Flunitrazepam 0.88 8 - 
rat GABAB [3H] GABA 5.2 0 - 
hum histamine H1 [3H] Pyrilamine 5.2 93 7.46 ± 0.20 
hum histamine H2 [3H] Tiotidine 5.1 37 - 
hum musucarinic M1 [3H] N-Methylscopolamine 0.37 9 - 
hum musucarinic M2 [3H] N-Methylscopolamine 0.37 21 - 
hum opiate δ [3H] Naltrindole 0.88 10 - 
hum opiate κ [125I] Diprenorphine 0.71 0 - 
hum opiate μ [125I] Diprenorphine 0.64 2 - 
gp serotonin 5-HT4 [3H] GR-113808 0.55 26 - 
hum serotonin 5-HT1B [3H] 5-HT 8.9 47 - 
hum serotonin 5-HT2A [3H] Ketanserin 0.48 35 - 
hum serotonin 5-HT2B [125I] LSD 0.29 79 117 ± 28 
hum serotonin 5-HT2C [3H] Mesulergine 1.8 20 - 
hum serotonin 5-HT3 [3H] GR-65630 0.47 0 - 
hum serotonin 5-HT5A [125I] LSD 0.020 2 - 
hum serotonin 5-HT6 [125I] LSD 0.020 14 - 
hum serotonin 5-HT7 [125I] LSD 0.020 73 288 ± 35 
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Table 4 
Incidence of vomiting and total emetic episode 
 
Drugs 
Dose  
(mg kg-1, po) 
Number of animals 
vomited/tested 
Total emetic episode 
Vehicle - 0/6 - 
DSP-1053 10 0/6 - 
 30 1/6 2 
 60 3/6 5.3 ± 1.0 
Paroxetine 1) 10 0/6 - 
 30 2/6 6, 8 
 60 **6/6 6.7 ± 0.5 
Incidence of vomiting is shown as the number of shrews that vomited / the number 
of shrews tested. **p < 0.01 vs. vehicle treatment, as analyzed by Fisher’s exact test. 
Total emetic episodes during the 1 h observation period were calculated for animals 
that vomited and expressed as mean ± S.E.M. 1) Mine et al., 2013. 
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Part-2 
DSR-98776, a novel selective mGlu5 receptor negative allosteric modulator with potent 
antidepressant and antimanic activity 
 
Abstract 
Modulation of monoaminergic systems has been the main stream of treatment for 
patients with mood disorders. However, recent evidence suggests that the glutamatergic 
system plays an important role in the pathophysiology of these disorders. This study 
pharmacologically characterized a structurally novel metabotropic glutamate 5 (mGlu5) 
receptor negative allosteric modulator, DSR-98776, and evaluated its effect on rodent 
models of depression and mania. First, DSR-98776 in vitro profile was assessed using 
intracellular calcium and radioligand binding assays. This compound showed 
dose-dependent inhibitory activity for mGlu5 receptors by binding to the same allosteric 
site as 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a known mGlu5 inhibitor. The in 
vivo therapeutic benefits of DSR-98776 were evaluated in common rodent models of 
depression and mania. In the rat forced swimming test, DSR-98776 (1-3 mg kg-1) 
significantly reduced rats immobility time after treatment for 7 consecutive days, while 
paroxetine (3 and 10 mg kg-1) required administration for 2 consecutive weeks to reduce 
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rats immobility time. In the mouse forced swimming test, acute administration of 
DSR-98776 (10-30 mg kg-1) significantly reduced immobility time. This effect was not 
influenced by 4-chloro-DL-phenylalanine methyl ester hydrochloride-induced 5-HT 
depletion. Finally, DSR-98776 (30 mg kg-1) significantly decreased 
methamphetamine/chlordiazepoxide-induced hyperactivity in mice, which reflects this 
compound antimanic-like effect. These results indicate that DSR-98776 acts as an orally 
potent antidepressant and antimanic in rodent models and can be a promising 
therapeutic option for the treatment of a broad range of mood disorders with depressive 
and manic states. 
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Purpose 
In Part-2, I report the in vitro profile of a structurally novel mGlu5 receptor negative 
allosteric modulator, DSR-98776, using intracellular calcium and radioligand binding 
assays. Furthermore, I evaluate the antidepressant and antimanic efficacy of this 
compound in the rat and mouse forced swimming test and in the mouse 
methamphetamine/chlordiazepoxide-induced hyperactivity model.  
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Materials and methods 
Animals 
In part-2, all animals were purchased from Charles River Laboratories Japan, Inc. 
(Kanagawa, Japan) and used after a quarantine period of 7 days. The rats and mice were 
housed in the same condition as part-1. 
 
Chemical reagents 
DSR-98776 
((3-fluorophenyl)[2-(5-fluoropyridin-2-yl)]-6,7-dihydoro[1,3]oxazolo[4,5-c]pyridin-5(4
H)-yl]methanone, Figure 1), paroxetine hydrochloride (paroxetine), and 
methamphetamine were synthesized in my laboratories. DSR-98776 was synthesized 
through amide-condensation reaction between 3-fluorobenzoyl chloride and 
2-(5-fluoropyridin-2-yl)-4,5,6,7-tetrahydrooxazolo[4,5-c]pyridine which was prepared 
from 4-fluoropicolinic acid according to the published procedure (Burdi et al., 2010) 
except that Burgess’ reagent was used instead of POCl3 in oxazole formation step. Total 
yield from 4-fluoropicolinic acid to DSR-98776 was 54%. PCPA 
(4-chloro-DL-phenylalanine methyl ester hydrochloride), chlordiazepoxide 
hydrochloride (chlordiazepoxide), lithium chloride (lithium), and carbamazepine were 
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purchased from Sigma Aldrich Japan (Tokyo, Japan). All radioligands were purchased 
from Perkin Elmer Japan (Kanagawa, Japan). For oral administration, DSR-98776, 
paroxetine, lithium, and carbamazepine were dissolved in 0.5% methylcellulose. For 
intraperitoneal (i.p.) administration, PCPA, chlordiazepoxide and methamphetamine 
were dissolved in saline. Dosing volume was determined based on each animal body 
weight measured in the morning of each administration day (5 mL kg-1 for rats and 10 
mL kg-1 for mice). 
 
Intracellular calcium assay 
The intracellular calcium assay was conducted using HEK 293 cells stably expressing 
cloned human mGlu receptors, i.e. mGlu1, 2, 4, 5, 6, and 8 receptors. The cells were 
cultured in DMEM (high glucose) supplemented with 10% dialyzed fetal bovine serum 
and 200 μg mL-1 G418 (culture medium), and transiently expressed apoaequorin as 
previously described (Stables et al., 1997). Gα16 subunit (for mGlu2 receptor) or 
G-protein chimera protein (for mGlu4, 6, and 8 receptors) was also expressed 
concomitantly with apoaequorin. The cells were plated at a density of 1500 (for mGlu2 
and 5 receptors), 2000 (for mGlu4 and 6 receptors), 4000 (for mGlu8 receptor) and 5000 
(for mGlu1 receptor) cells/50 μL/well into black 384-well plates with clear bottoms and 
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incubated overnight at 37°C in the presence of 5% CO2. The following day, 10 μL of 
assay buffer (1x Hanks supplemented with 20 mM HEPES and 0.1% BSA) containing 
30 nM of coenlenterazine-h (for mGlu1, 2, 4, 5, and 8 receptors) or 3 μM of ViviRen (for 
mGlu6 receptor) was loaded into each well containing the cells. After 4 h incubation at 
R.T., 10 μL of assay buffer containing each test-compound at the indicated 
concentrations was applied to the cells. Two minutes later, assay buffer containing 20 
μM (for mGlu2 receptor), 10 μM (for mGlu4 receptor), 2 μM (for mGlu5 and 8 receptors), 
100 μM (for mGlu1 receptor) or 200 μM (for mGlu6 receptor) of glutamate was added, 
and the fluorescence produced was measured by a functional drug screening system 
(FDSS7000 Hamamatsu Photonics K.K., Japan). As numerical treatment, 2 s was 
integrated for 1 min evaluation.  
 
Radioligand binding assay 
In a total volume of 200 μL, 1 μL of each test-substance (glutamate, MPEP or 
DSR-98776) or DMSO, 50 μL of assay buffer [15 mM Tris-HCl (pH7.6) containing 120 
mM NaCl, 100 mM KCl, 25 mM CaCl2, and 25 mM MgCl2 for allosteric binding or 20 
mM Tris-HCl (pH7.2) containing 2 mM CaCl2 and 2 mM MgCl2 for orthosteric 
binding] containing a radioligand (2 nM of [3H]-MPEP for alloseric binding or 37.5 nM 
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of [3H]-quisqualic acid for orthosteric binding), and 149 μL of assay buffer containing 
HEK293 cell membranes (0.15 μg μL-1) stably expressing cloned human mGlu5 
receptor were mixed. The reaction was started by addition of the cell membranes. To 
evaluate the binding affinity for both the allosteric and orthosteric sites, the samples 
were reacted at 25°C for 1 h in a dry block bath. GF/B glass filters coated for 1 h with 
0.1% polyethyleneimine and dried under low pressure were used to terminate the 
reaction by filtration under vacuum. The glass filters were washed with 200 μL of 
ice-cold 50 mM Tris-HCl (pH7.6) and placed in scintillation vials with 2 mL of ACS II 
scintillation fluid (GE health care bioscience). Measurement of radioactivity was 
conducted as described in part-1. 
 
Off-target radioligand binding assays and enzyme assays  
To determine DSR-98776 interaction with off-target receptors, transporters, channels, 
and enzymes, 43 binding assays and 2 enzyme assays (catechol-O-methyltransferase 
and monoamine oxidase-A) were conducted on my behalf by Eurofines Panlabs Inc. 
The binding assays were carried out using standard techniques as summarized in Table 1. 
As for the enzyme assays, pig catechol-O-methyltransferase activity was evaluated 
using 3.0 mM catechol + S-adenosyl-L-[methyl-3H]-methionine as substrate and the 
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amount of the produced [3H]-guaiacol was quantitated. Monoamine oxidase-A activity 
was evaluated using 50 μM kynuramine as substrate and the amount of the formed 
4-hydroxyquinoline was quantitated. 
 
Ex vivo inhibition of [3H]-3-methoxy-5-pyridin-2-ylethynylpyridine (MPEPy) 
binding 
One hour after administration of MPEP or DSR-98776 to 5-week old male CD1 (ICR) 
mice (n=4 per group) and 7-week old male SD rats (n=6 per group), the animals were 
sacrificed, and the brain was rapidly removed and immediately dissociated on ice into 
the forebrain (for mice) or frontal cortex (for rats). The prepared tissues were 
homogenized in ice-cold 50 mM Tris-HCl (pH7.5) containing 0.9% NaCl (assay buffer) 
using a motor-driven glass-Teflon homogenizer, and subsequently diluted with the assay 
buffer to 25 mg mL-1. In a total volume of 52 μL, 1 μL of DMSO for measurement of 
total binding or 10 mM of MPEP for measurement of non-specific binding, 1 μL of 
assay buffer [50 mM Tris-HCl (pH7.5) containing 0.9% NaCl] containing 52 nM of 
[3H]-MPEPy, and 50 μL of the prepared tissue membranes were mixed. The reaction 
was started by addition of the tissue membranes and allowed to proceed for 1 h at R.T. 
GF/B glass filters coated for 1 h with 0.5% polyethyleneimine and dried under low 
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pressure were used to terminate the reaction by filtration under vacuum. The glass filters 
were washed with 200 μL of ice-cold 50 mM Tris-HCl (pH7.5) and placed in 
scintillation vials with 2 mL of ACS II scintillation fluid (GE health care bioscience). 
Measurement of radioactivity was conducted as described in part-1. 
 
Rat forced swimming test 
The test was performed using 7-week old male Wistar rats. Test-compounds 
antidepressant-like activity was assessed as described in part-1 except for conducting 
swimming test on day 7 or 14. 
 
Mouse forced swimming test 
The test was performed using 5-week old male CD1 (ICR) mice. Test compounds 
antidepressant-like activity was assessed using an automatic behavior analysis system, 
SCANET AQ (Melquest Ltd., Toyama, Japan). One hour after dosing with DSR-98776, 
paroxetine or the vehicle, each animal was gently placed into a plastic cylinder (22.5 cm 
in height, 14 cm in diameter) containing 5.0 L of water set at 25 ± 1°C. The animal 
immobility time was recorded for 6 min and determined in seconds by SCANET AQ. 
Animals dosing and swimming test were conducted between 1:00PM and 5:00PM. To 
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deplete 5-HT, the mice were administered 300 mg kg-1 of PCPA, an irreversible 
tryptophan hydroxylase inhibitor, once a day for 3 consecutive days between 7:00AM 
and 7:00PM. The next day, PCPA was administered in the morning, followed by the 
forced swimming test as described above.  
 
Methamphetamine/chlordiazepoxide induced hyperactivity in mice  
Thirty minutes after oral administration of dosing suspensions to 8-week old C57/BL6J 
mice, methamphetamine (10 mg kg-1), a mixture of methamphetamine (10 mg kg-1) and 
chlordiazepoxide (4 mg kg-1), or saline was administered to each mouse. The animal 
was then placed in a plastic cage (25 x 38 x 30.5 cm), and its behavior was recorded for 
90 min. After the test session, the recordings were analyzed by an Etho Vision 3.1 
system (Sophia Scientific Co., Ltd., Aichi, Japan). 
 
Spontaneous locomotion 
This experiment was performed using 7-week old male Wistar rats. One hour after 
administration of DSR-98776 or 0.5% methylcellulose, the animals were placed in 
plastic cages, and their spontaneous locomotion was measured for 15 min by an 
automatic behavior analyzing system, SCANET AQ (Melquest Ltd., Toyama, Japan). 
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Data analysis 
EC50 values of glutamate, IC50 values of DSR-98776 and MPEP in the intracellular 
calcium assay, and RO50 value of DSR-98776 and MPEP in ex vivo binding assay were 
determined using Dx calculation (logistic curve fitting) with measured value input 
function in Stat Prelinica Version 1.0.3295. In the rat and mouse forced swimming test, 
differences in immobility time and spontaneous locomotion between test-compounds 
treated groups and the vehicle treated group were analyzed with one-way ANOVA 
followed post hoc parametric Dunnett’s multiple comparison test. In the 
methamphetamine/chlordiazepoxide-induced hyperactivity model, differences in 
spontaneous locomotion between the test compound-saline treated group vs. 
vehicle-saline treated group, compound-methamphetamine treated group vs. vehicle- 
methamphetamine treated group, and compound-methamphetamine/chlordiazepoxide 
treated group vs. vehicle-methamphetamine/chlordiazepoxide treated group were 
analyzed with one-way ANOVA followed post hoc parametric Dunnett’s multiple 
comparison test. In PCPA induced 5-HT depletion model, the effect of PCPA, 
DSR-98776, and paroxetine on immobility time and the interaction between PCPA and 
DSR-98776 or paroxetine were analyzed with two-way ANOVA. Statistical analysis in 
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the ANOVA and the parametric Dunnett’s multiple comparison tests was performed 
using SAS system, and values of p < 0.05 (two-tailed test) were considered as 
statistically significant. 
 
70 
 
Results 
Intracellular calcium assay  
Glutamate concentration-dependently increased intracellular calcium concentration in 
HEK293 cells stably expressing cloned human mGlu5 receptors with an EC50 value of 
311.1 ± 50.3 nM (mean ± S.E.M. n=3) (Figure 2). To confirm the inhibitory activity of 
DSR-98776 on mGlu5 receptors, changes in the concentration-response curve for 
calcium response stimulated by glutamate in the presence of DSR-98776 at the 
concentration of 0, 30, 100, 300 nM, and 1 μM were evaluated. The effects of MPEP at 
0, 3, 10, 30, and 100 nM on calcium concentration-response curves were also evaluated. 
DSR-98776 shifted glutamate concentration-response curve to the right and decreased 
maximal response (Figure 2A). These changes were consistent with those produced by 
MPEP (Figure 2B). DSR-98776 and MPEP attenuated the increase in calcium response 
caused by 1 μM of glutamate (a concentration that gave about 80% of maximum agonist 
response) with IC50 values of 66.7 ± 5.9 and 3.9 ± 0.7 nM, respectively.  
 
Radioligand binding assay 
The binding site of DSR-98776 for the mGlu5 receptor was determined using 
radioligands capable of binding to either the orthosteric or allosteric site of mGlu5 
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receptor. MPEP (1 μM) and DSR-98776 (10 μM) did not inhibit the binding of 
[3H]-quisqualic acid to mGlu5 receptor orthosteric site. The relative inhibitory percents 
to total binding were -11.3 ± 5.1 and -1.4 ± 6.2%, respectively, mean ± S.E.M. (n=3, 
Figure 3A). On the other hand, glutamate (1 mM), an intrinsic ligand for the mGlu5 
receptor, almost completely blocked the binding of [3H]-quisqualic acid with a relative 
inhibitory percent to total binding of 91.9 ± 6.9%, mean ± S.E.M. (n=3). As for mGlu5 
receptor allosteric site, both MPEP (1 μM) and DSR-98776 (10 μM), but not glutamate 
(1 mM), inhibited the binding of [3H]-MPEP to this site [relative % inhibition of 98.2 ± 
1.3 (MPEP), 92.9 ± 1.0 (DSR-98776), and -19.5 ± 18.5 (glutamate), mean ± S.E.M. 
n=3] (Figure 3B). 
 
DSR-98776 effects on off-target receptors, channels, transporters and enzymes 
DSR-98776 (1 and 10 μM) showed much weaker inhibitory activity for other mGlu 
receptors, including mGlu1, 2, 4, 6, and 8 receptors than for the mGlu5 receptor (Table 1). 
In addition, in the 43 conducted binding assays for various receptors, channels, and 
transporters, DSR-98776 showed little affinity (< 50% inhibition at 10 μM) for all the 
off-targets listed in Table 2. Moreover, DSR-98776 did not have any inhibitory activity 
on pig catechol-O-methyltransferase and human monoamine oxidase-A even at 10 μM 
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(-8 and 4 %, respectively). 
 
DSR-98776 ex vivo inhibition of [3H]-MPEPy binding to mGlu5 receptor 
Next, DSR-98776 and MPEP occupancy of mGlu5 receptor was evaluated by ex vivo 
inhibition of [3H]-MPEPy binding to this receptor. In the mouse forebrain, DSR-98776 
and MPEP produced a dose-dependent mGlu5 receptor occupancy with RO50 (the dose 
causing 50% of receptor occupancy) values of 5.5 and 5.6 mg kg-1, respectively (Figure 
4A). In the rat cortex, DSR-98776 also produced dose-dependent receptor occupancy 
with an RO50 value of 0.74 mg kg
-1. In addition, occupancy rates after daily oral 
administration of DSR-98776 for 4 days were almost equivalent to the occupancy rate 
produced by DSR-98776 after single oral administration (Figure 4B). 
 
DSR-98776 antidepressant-like effect in the rat forced swimming test  
As shown in Figure 5A, DSR-98776 significantly decreased immobility time following 
a 7-day consecutive administration at 1 and 3 mg kg-1 compared to the vehicle [F(3,38) 
= 6.52, p < 0.01]. This compound had no effect on spontaneous locomotion in an open 
field throughout the treatment period [F(3,20) = 0.65, p > 0.05] (Figure 5B). On the 
other hand, animals treated with paroxetine (3 and 10 mg kg-1) for 14 days reduced 
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immobility time compared to the animals treated with the vehicle [F(3,33) = 3.29, p < 
0.05] (Figure 5C). Treatment with paroxetine for 7-day had no effect on rats immobility 
time [F(2,15) = 0.09, p > 0.05] (Figure 5D). 
 
DSR-98776 antidepressant-like effect in the mouse forced swimming test  
As shown in Figure 6A, DSR-98776 at 10 and 30 mg kg-1 significantly decreased 
immobility time compared to vehicle treatment [F(3,32) = 8.70, p < 0.01]. Mice treated 
with paroxetine at 30 mg kg-1 also showed significant reduction of immobility time 
[F(3,32) = 5.15, p < 0.01] (Figure 6B). 
 
DSR-98776 antidepressant-like effect in mice with depleted 5-HT  
The antidepressant-like effects of DSR-98776 and paroxetine in mice with depleted 
5-HT (PCPA-treated mice) were evaluated in the forced swimming test. Two-way 
ANOVA revealed that DSR-98776 (30 mg kg-1) significantly decreased mice immobility 
time [F(1,59) = 24.11, p < 0.001]. As shown in Figure 7A, PCPA alone didn’t alter mice 
immobility time compared to the vehicle [F(1,59) = 0.39, p > 0.05], and it didn’t 
significantly affect DSR-98776-induced decrease in mice immobility time [interaction: 
F(3,59) = 0.73, p > 0.05]. Although paroxetine also significantly reduced mice 
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immobility time [F(1,60) = 7.94, p < 0.01], unlike DSR-98776, pretreatment with PCPA 
inhibited paroxetine-induced decrease in mice immobility time [interaction: F(1,60) = 
4.01, p < 0.05] (Figure 7B). 
 
DSR-98776 anti-manic effect in methamphetamine/chlordiazepoxide-induced 
hyperactivity in mice  
As shown in Figure 8A, DSR-98776 (30 mg kg-1) significantly decreased 
methamphetamine/chlordiazepoxide-induced hyperactivity [F(2,27) = 9.17, p < 0.01], 
which reflects manic state. On the other hand, DSR-98776 had no significant effect on 
baseline locomotor activity in the vehicle-vehicle treated group and in 
methamphetamine alone-induced hyperactivity [baseline, F(2,21) = 2.16, p > 0.05; 
methamphetamine alone, F(2,27) = 5.21, p < 0.05 (Dunnet’s post hoc test; p > 0.05 at 
10 and 30 mg/kg vs. vehicle treated group)]. As with DSR-98776, lithium (100 mg kg-1), 
which is clinically used as a mood stabilizer, reduced 
methamphetamine/chlordiazepoxide-induced hyperactivity [F(2,13) = 7.04, p < 0.01] 
without affecting baseline locomotor activity and methamphetamine alone-induced 
hyperactivity [baseline, F(2,15) = 3.63, p > 0.05; methamphetamine alone, F(2,13) = 
0.61, p > 0.05] (Figure 8B). Carbamazepine (100 mg kg-1) on the other hand, reduced 
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not only methamphetamine/chlordiazepoxide-induced hyperactivity [F(2,13) = 18.46, p 
< 0.01], but also methamphetamine alone-induced hyperactivity [baseline, F(2,14) = 
3.18, p > 0.05; methamphetamine alone, F(2,14) = 29.22, p < 0.01] (Figure 8C).
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Discussion 
Most of the reported mGlu5 receptor negative allosteric modulators have a typical 
di-substituted alkyne structure as the central scaffold (Gasparini et al., 1999; Kubas et 
al., 2013). However, I succeeded in obtaining a selective mGlu5 receptor negative 
allosteric modulator, DSR-98776, without this core structure. My purpose in this study 
was to characterize this compound in vitro profile and to elucidate its in vivo therapeutic 
benefits in common rodent models of depression and mania. As shown in Figure 2, 
DSR-98776 shifted glutamate concentration-response curve to the right and decreased 
its maximal response in the intracellular calcium assay with cells expressing the human 
mGlu5 receptor. In addition, I found that DSR-98776 did not affect the binding of 
[3H]-quisqualic acid to the orthosteric site of mGlu5 receptor, but completely suppressed 
the binding of [3H]-MPEP to the allosteric site of mGlu5 receptor. These findings 
indicate that DSR-98776 acts as a mGlu5 receptor noncompetitive antagonist that 
occupies the same allosteric site of mGlu5 receptor as MPEP, despite the two 
compounds structural differences. On the other hand, the IC50 value of DSR-98776 for 
glutamate induced calcium efflux was 66.7 ± 5.9 nM, which was about 17 times weaker 
than that of MPEP. Porter et al. (2005) have also reported another mGlu5 receptor 
negative allosteric modulator, fenobam, that has weaker functional potency than MPEP 
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and MTEP. In addition, a recent report has shown that Novartis’ Mavoglurant 
(AFQ-056) exhibits an IC50 value of 71.6 nM in intracellular calcium detection assay 
(Kubas et al., 2013). These results indicate that the inhibitory activity of DSR-98776 on 
the mGlu5 receptor is comparable to that of representative mGlu5 receptor negative 
allosteric modulators that show promising efficacy in in vivo models. Furthermore, my 
off-target radiobinding assay together with functional and enzyme assays confirmed that 
DSR-98776 is a highly selective mGlu5 receptor negative allosteric modulator. 
  As mGlu5 receptor inhibitors are believed to have beneficial effects on various 
depressive states  (Pałucha et al., 2005; Pałucha and Pilc, 2007; Pilc et al., 2002; 
Swanson et al., 2005; Witkin et al., 2007), I evaluated the effects of DSR-98776 in the 
rat and mouse forced swimming test. DSR-98776 significantly reduced rats immobility 
time without affecting spontaneous locomotion. Rat forced swimming test is widely 
used as a behavioral screening tool for assessment of the benefits of all major classes of 
antidepressant, including tricyclic antidepressants, monoamine oxidase inhibitors, 
atypical antidepressants, and electroconvulsive shock (Borsini and Meli, 1988). A 
delayed onset of the effect of clinical treatments can be mimicked in this test, because 
low dose of antidepressants produce antidepressant-like efficacy only after chronic 
treatment (Detke et al., 1997; Trivedi et al., 2006). In this study, DSR-98776 decreased 
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rats immobility time after 7 days treatment, while treatment with paroxetine, a 
representative SSRI, required 2 weeks for comparable efficacy. These results indicate 
that DSR-98776 would have earlier clinical onset than SSRIs in the treatment of 
depressive states. However, it would be interesting to evaluate the fast onset action of 
this compound in representative chronic models, such as chronic mild stress model, to 
support my results in the rat forced swimming test. In contrast to the significant 
dose-dependent efficacy of DSR-98776 in the forced swimming test, Pałucha et al. 
(2005) have shown that MTEP does not influence rats immobility time in the Porsort’s 
forced swimming test, but significantly alters mice immobility time in the tail 
suspension test. In this study, DSR-98776 was daily administered for 7 consecutive days 
compared to 3 times treatment with MTEP in Pałucha et al. report. In addition, it is 
believed that the dose of MTEP used in that report is beyond the effective dose range of 
MTEP (Pałucha-Poniewiera et al., 2014). Thus, I consider that appropriate dose range 
coupled with appropriate administration regimen are necessary for assessing drug 
efficacy in the rat forced swimming test. 
  Next, I confirmed the efficacy of DSR-98776 in the mouse forced swimming test and 
investigated whether this efficacy is achieved via serotonergic mechanisms using PCPA, 
which is frequently used to generate SSRI-resistant depression models with depleted 
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central 5-HT (Koe and Weissman, 1966; Pałucha-Poniewiera et al., 2014). In naïve mice, 
DSR-98776 and paroxetine significantly and dose-dependently reduced mice 
immobility time, suggesting an antidepressant-like effect. On the other hand, 
DSR-98776 showed significant antidepressant-like efficacy in both of PCPA- and 
saline-treated mice, while pretreatment with PCPA blocked the efficacy of paroxetine. 
These results indicate that DSR-98776 shows antidepressant-like efficacy via 5-HT 
independent mechanisms. In contrast to these results, Pałucha-Poniewiera et al. (2014) 
have shown the involvement of serotonergic system activation in the antidepressant-like 
effect of MTEP. Furthermore, Stachowicz et al. (2007) showed that MTEP 
dose-dependently increases 5-HT release in PFC in rat microdialysis study. It is difficult 
to show a reasonable explanation for these discrepancies, because MTEP is reported to 
be a selective for mGlu5 receptor (Cosford et al., 2003). However, Cosford et al. (2003) 
showed that MTEP had weak monoamine oxidase-A inhibitory activity, which would 
contribute to inhibition of serotonin metabolisms. These findings suggest that a part of 
the antidepressant efficacy of MTEP is based on enhancement of 5-HT 
neurotransmission. Taken together, these results suggest that DSR-98776 would have 
fast acting antidepressant efficacy based on 5-HT independent mechanisms. 
  Inhibition of mGlu5 receptors is expected to be beneficial not only as 
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antidepressant-like effect, but also as mood stabilizing effect. In addition to the fact that 
glutamine/glutamate ratio is significantly high in anterior cingulate cortex and 
parieto-occipital cortex in bipolar disorder (Öngür et al., 2008), it is reported that 
lithium, which is frequently used as mood stabilizer for patient with mania, robustly 
protects neurons against excitotoxicity, probably by reducing glutamatergic 
overstimulation (Nonaka et al., 1998). Other clinically effective drugs, such as 
antiepileptics are known to inhibit glutamate activity (Krystal et al., 2002). From this 
evidence, I considered that DSR-98776, which can modulate glutamatergic 
neurotransmission by inhibiting mGlu5 receptor, would show a mood stabilizing effect. 
The antimanic effect of DSR-98776 was evaluated in 
methamphetamine/chlordiazepoxide-induced hyperactivity in mice. In this model, mice 
are treated with a mixture of a psychostimulant, including methamphetamine and 
D-amphetamine plus chlordiazepoxide. To distinguish antipsychotic drugs from mood 
stabilizers, a separate group of animals are treated with methamphetamine alone. Thus, 
test-drugs mood stabilizing efficacy can be detected by their efficacy against 
hyperactivity induced by a mixture of methamphetamine plus chlordiazepoxide and 
their lack of efficacy against hyperactivity induced by methamphetamine alone (Arban 
et al., 2005; Okada et al., 1990). In the present study, I also examined the effects of 
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lithium and carbamazepine as control drugs. Lithium is able to selectively reduce the 
hyperactivity induced by a mixture of methamphetamine plus chlordiazepoxide, while 
carbamazepine reduces not only the hyperactivity induced by a mixture of 
methamphetamine plus chlordiazepoxide, but also the hyperactivity induced by 
methamphetamine alone. On the other hand, DSR-98776, like lithium, significantly 
reduced the hyperactivity induced by a mixture of methamphetamine plus 
chlordiazepoxide at the dose that had no effect on basal activity and hyperactivity 
induced by methamphetamine alone. Arban et al. (2005) showed that carbamazepine 
and lamotorigine diminish the hyperactivity induced by methamphetamine alone and 
discussed that this effect on sodium channels would prevent the dopamine mediated 
modulation by D-amphetamine. In terms of the effect on dopamine neurotransmission, 
it is reasonable that DSR-98776 has no effect on the hyperactivity induced by 
methamphetamine alone, because this compound does not have binding affinity for 
dopamine related targets. Furthermore, it has been reported that lithium attenuates 
calcium release after desensitization of Group I mGlu receptors, including mGlu5 
receptor (Sourial-Bassillious et al., 2009). This finding indicates that DSR-98776 has a 
mood stabilizing effect based on non-dopaminergic mechanisms.  
  In conclusion, my results show that DSR-98776, a novel compound without typical 
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di-substituted alkyne, has a highly selective mGlu5 receptor negative allosteric 
modulating effect and potent antidepressant-like efficacy. Furthermore, DSR-98776 has 
antimanic-like efficacy as indicated by the results in a rodent mania model. These 
findings indicate that DSR-98776 has great potential in the treatment of a broad range 
of mood disorders. 
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Figures and Tables 
 
 
Figure 1 
Chemical structure of DSR-98776 
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Figure 2 
DSR-98776 and MPEP inhibition of calcium efflux in HEK293 cells 
expressing the human mGlu5 receptor. (A, B) Effects of DSR-98776 and MPEP 
on concentration–response curve of glutamate for human mGlu5 receptor. Data 
symbols represent the maximum fluorescent signal obtained at each 
concentration as mean ± S.E.M (n=3). Each single experiment was performed 
in quadruplicate. 
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Figure 3 
Inhibition of labeled compounds binding to the orthosteric or allosteric site of 
mGlu5 receptor. (A) Glutamate, MPEP and DSR-98776 inhibition of 
[3H]-quisqualic acid binding to the orthosteric site of mGlu5 receptor. Each bar 
represents the mean ± S.E.M (n=3). (B) Test-compounds inhibition of 
[3H]-MPEP binding to the allosteric site of mGlu5 receptor. Each bar represents 
the mean ± S.E.M (n=3). Each single experiment was performed in duplicate. 
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Figure 4 
Ex vivo mGlu5 occupancy by DSR-98776 and MPEP. (A) Effect of 1 h 
pretreatment with DSR-98776 or MPEP on ex vivo binding of [3H]-MPEPy in 
the mouse forebrain. (B) Effect of single or 4 days administration of 
DSR-98776 on ex vivo binding of [3H]-MPEPy in the rat frontal cortex. In both 
cases, occupancy rate was expressed as percentage of receptor labelling in the 
corresponding brain areas (forebrain for mice or cortex for rats) of the 
vehicle-treated animals. Each symbol represents the mean ± S.E.M (n=4 for 
mice or n=6 for rats). 
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Figure 5 
(A, C and D) Effects of DSR-98776 and paroxetine on immobility time in the 
forced swimming test in rats. Each bar represents the mean ± S.E.M of 
immobility time during a 6 min test session (n=6 (for D) or 12 (for A and C) 
per each group). (B) Effect of DSR-98776 on locomotion. Each bar represents 
the mean ± S.E.M of locomotion during a 15 min period, starting 1 h after 
administration of DSR-98776 (n=6 per each group). **p < 0.01, compared with 
the vehicle-treated group using parametric Dunnett’s multiple comparison test, 
following significant results of one-way ANOVA.  
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Figure 6 
Effects of DSR-98776 (A) and paroxetine (B) on immobility time in the forced 
swimming test in mice. Each bar represents the mean ± S.E.M of immobility 
time during a 6 min test session (n=9 per each group). **p < 0.01, compared 
with the vehicle-treated group using parametric Dunnett’s multiple comparison 
test, following significant results of one-way ANOVA. 
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Figure 7 
Effects of DSR-98776 (A) and paroxetine (B) on immobility time in the forced 
swimming test in PCPA treated mice. Values are expressed as the mean ± 
S.E.M and were analyzed by two-way ANOVA. **p < 0.01 for the main effects 
of DSR-98776 and paroxetine vs. the control group; #p < 0.05 for the 
interaction between paroxetine and PCPA treatment. 
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Figure 8 
Effects of DSR-98776 (A), lithium (B) and carbamazepine (C) on basal activity, 
methamphetamine (MAP)- or MAP/chlordiazepoxide (CDP)-induced 
hyperactivity in mice. Each bar represents the mean ± S.E.M of locomotion 
during a 90 min period, starting 1 h after administration of each test-compound 
(n=5-10). *p < 0.05, **p < 0.01, compared with the vehicle-treated group using 
parametric Dunnett’s multiple comparison test, following significant results of 
one-way ANOVA.  
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Table 1 
DSR-98776 (1 and 10 μM) inhibition of calcium efflux by stimulation of various mGlu 
receptors 
 
Target 
Conc.  
(M) 
% inhibition 
mGlu1 1 4.2  
 10 -2.3  
mGlu2 1 -4.7  
 10 -14.0  
mGlu4 1 -25.7  
 10 28.0  
mGlu6 1 -15.4  
 10 -20.8  
mGlu8 1 3.8  
  10 6.6  
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Table 2 
DSR-98776 (10 μM) inhibition of radioligand binding to various receptors, channels 
and transporters 
 
Target Radioligand 
Conc. 
(nM) 
% 
inhibition 
  Target Radioligand 
Conc. 
(nM) 
% 
inhibition 
rat adrenergic α1 [3H] Prazosin 0.25  -9  hum musucarinic M1 [3H] N-Methylscopolamine 0.80  5 
rat adrenergic α2 [3H] Rauwolscine 0.70  1  hum nicitnic acetylcholine [125I] Epibatidine 0.10  -3 
rat adrenergic β [3H] Dihydroalprenolol 0.25  1  rat opiate [3H] Naloxone 1.0  20 
rat calcium channel L-type [3H] Diltiazem 2.0  4  rat potassium Channel [KA] [125I] α-Dendrotoxin 0.010  -1 
rat calcium channel L-type [3H] Nitrendipine 0.10  -6  hum potassium Channel [KATP] [3H] Glyburide 5.0  12 
rat calcium channel L-type [3H] D-888 0.40  2  rat potassium Channel [SKCA] [125I] Apamin 0.0050  1 
rat calcium channel N-type [125I] ω-Conotoxin 0.010  0  hum serotonin 5-HT1A [3H] 8-OH-DPAT 1.5  2 
hum dopamine D1 [3H] SCH-23390 1.4  10  hum serotonin 5-HT1B [3H] GR125743 1.0  9 
hum dopamine D2L [3H] Spiperone 0.16  4  hum serotonin 5-HT2A [3H] Ketanserin 0.50  0 
hum dopamine D3 [3H] Spiperone 0.70  2  hum serotonin 5-HT2B [3H] LSD 1.2  -8 
rat GABAA [3H] TBOB 3.0  1  hum serotonin 5-HT2C [3H] Mesulergine 1.0  -1 
rat GABAA [3H] Flunitrazepam 1.0  10  hum serotonin 5-HT3 [3H] GR-65630 0.69  8 
rat GABAA [3H] Muscimol 1.0  49  gp serotonin 5-HT4 [3H] GR-113808 0.70  5 
rat GABAB [3H] CGP-54626 0.60  9  hum serotonin 5-HT6 [3H] LSD 1.5  0 
rat glutamate, AMPA [3H] AMPA 5.0  -16  hum serotonin 5-HT7 [3H] LSD 5.5  7 
rat glutamate, kainate [3H] Kainic acid 5.0  4  rat choline transporter [3H] Hemicholinium-3 0.75  5 
rat glutamate, NMDA [3H] CGP-39653 2.0  12  hum DAT [125I] RTI-55 0.15  7 
rat glutamate, NMDA [3H] TCP 4.0  -2  rat GABA transporter [3H] GABA 6.0  -7 
rat glycine [3H] Strychnine 10  -19  rat glycine transporter [3H] Glycine 0.050  7 
hum histamine H1 [3H] Pyrilamine 1.2  0  hum NET [125I] RTI-55 0.20  1 
hum histamine H2 [125I] Aminopotentidine 0.10  -14  hum SERT [3H] Paroxetine 0.40  10 
hum imidazoline I2 [3H] Idazoxan 2.0  -19           
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Summary and Conclusion 
This study characterized the in vitro pharmacological profiles of two structurally novel 
antidepressant candidates, i.e. DSP-1053, a 5-HT reuptake inhibitor with 5-HT1A 
receptor partial agonistic activity, and DSR-98776, a selective mGlu5 receptor negative 
allosteric modulator, and demonstrated the superior therapeutic benefits of these 
compounds compared to conventional SSRIs in rodent mood disorder models.  
  First, both compounds showed earlier therapeutic onset than conventional SSRIs. 
Although activation of 5-HT1A receptor is reported to fasten SSRIs therapeutic onset, I 
was able to confirm this hypothesis by directly comparing the efficacy of DSP-1053 to 
that of paroxetine, a representative SSRI, in the rat forced swimming test and olfactory 
bulbectomy test, both of which are suitable paradigms for investigating antidepressants 
onset. On the other hand, previous reports have shown that mGlu5 receptor negative 
allosteric modulators lack this feature. Therefore, this report shows for the first time that 
a selective mGlu5 receptor negative allosteric modulator has faster therapeutic onset 
than conventional SSRIs. These results indicate that addition of 5-HT1A partial agonistic 
activity or mGlu5 receptor inhibitory activity to 5-HT reuptake inhibition improves 
antidepressants therapeutic onset. Because delayed therapeutic onset is one of the main 
drawbacks of current antidepressants, these results are important for the development of 
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new medications for major depressive disorder. 
  Using DSP-1053, we demonstrated in this study that partial activation of the 5-HT1A 
receptor contributes to a fast adaptation to the feeling of nausea and therefore reduction 
in emetic episodes. Since patients adherence to antidepressants is directly related to the 
frequency and intensity of side effects, this finding would be useful in alleviating 
antidepressants gastrointestinal side effects and reducing treatment incompletion rate. 
This study also showed that the mGlu5 receptor negative allosteric modulator 
DSR-98776 is effective not only for the depressive state but also for the manic state of 
mood disorder. There remain significant unmet medical needs for the treatment of 
mania, because mania symptoms significantly affect patient’s life and can be controlled 
by mood stabilizers and atypical antipsychotics, both of which have severe side effects. 
Although the precise mechanism of the antimanic effect of mGlu5 receptor inhibition is 
unknown, improved monoaminergic transmission and channel blocking, which are the 
main mechanisms of action of current antidepressants, are not likely to be involved in 
the downstream efficacy of DSR-98776 based on the in vitro pharmacological profiling. 
Therefore, my findings indicate that modulation of glutamatergic neurotransmission, 
including inhibition of the mGlu5 receptor, is a promising therapeutic option for patients 
with bipolar disorder. 
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  In conclusion, I have shown in this study that the newly synthesized antidepressant 
candidate DSP-1053 and DSR-98776 show superior therapeutic benefits than available 
antidepressant. Since all current antidepressants, including tricyclic antidepressants, 
SSRIs, SNRIs and monoamine oxidase inhibitors, act by enhancing 5-HT and 
norepinephrine concentration in the synaptic cleft, a broad number of receptors, 
including both target and off-target receptors are simultaneously stimulated. Therefore, 
drugs with reduced side effects and improved efficacy by working to specific receptors 
are expected to be promising approach for future drug development. In addition, 
focusing on neurotransmitters other than the monoamines is obviously a promising 
approach for the discovery of new antidepressant. A number of effective 
neurotransmitters, including several neuropeptides and steroid hormones have been 
reported. Among them, glutamatergic neurotransmission is considered to be the most 
promising target due to the positive results of a number of clinical and non-clinical 
studies. This study demonstrated that both the 5-HT1A receptor and mGlu5 receptor are 
promising targets to compensate for the shortcomings of current antidepressants. In the 
future, not only further non-clinical evidences but also clinical evidences are expected 
to be piled up to make this research achievement helpful for patients who are unsatisfied 
with today’s armamentarium. 
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